Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

Coffee and the heart – four strong cups a day is beneficial finds study

According to a new study four cups of strong coffee might be the amount that would keep the hearts of older adults healthy. The latest study titled, “CDKN1B/p27 is localized in mitochondria and improves respiration-dependent processes in the cardiovascular system—New mode of action for caffeine,” was published on 21st of June 2018 in the journal PLOS Biology.

25 Jun 2018

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Spending on cancer drugs in the United States has nearly doubled in the past five years and continues to grow, imposing substantial financial burden on patients with cancer.

18 Apr 2018

Researchers use innovative method to screen kinases for cancer drug's effectiveness

In recent years, a powerful suite of drugs known as kinase inhibitors have been developed to treat cancer and other diseases. Primary targets of such drugs include a family of receptor tyrosine kinases (RTKs) which protrude from cell surfaces like antennae and can activate cancer-related pathways in virtually all types of cancer when signaling molecules bind with them.

5 Feb 2018

Scientists synthesize new multifunctional compound that has anti-tumor properties

A research team of the UNN Faculty of Chemistry led by Professor Alexei Fedorov has developed and synthesized a new multifunctional compound that possesses anti-tumor properties that are due to several independent effects.

2 Feb 2018

Leading medical societies update molecular testing guideline for lung cancer

Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer, the most common cause of cancer death worldwide.

24 Jan 2018

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

26 Dec 2017

Overcoming Challenges of Assays of Complex Cellular Models with Real-Time Live-Cell Analysis

There's a continued drive towards making in vitro assays ever more translational towards in vivo models and ultimately the clinic. This ties in with the resurgence of phenotypic screening and is a response to the perceived poor translation of the traditional simple cell-based assays, often developed to study just single protein targets.

From Sartorius 5 Dec 2017

New targeted treatment could benefit patients with certain pancreatic tumors

Researchers at the University of Cincinnati College of Medicine have shown that a new targeted treatment could benefit patients with certain pancreatic tumors by preventing spread of the cancer and protecting their heart from damage--a direct result of the tumor.

1 Dec 2017

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

Study identifies promising treatment to reduce brain injury in babies

Research-clinicians at Children's National Health System led the first study to identify a promising treatment to reduce or prevent brain injury in newborns who have suffered hypoxia-ischemia, a serious complication in which restricted blood flow deprives the brain of oxygen.

10 Nov 2017

FDA grants approval to first treatment for rare blood cancer

The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood.

7 Nov 2017

FDA approves new drug Zelboraf for Erdheim-Chester disease

The United States Food and Drugs Administration (FDA) has approved Zelboraf (vemurafenib), a drug for the treatment of adults with a are type of blood cancer called Erdheim-Chester Disease or ECD.

6 Nov 2017

FDA grants accelerated approval to new treatment for mantle cell lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.

1 Nov 2017

New approaches to treat aggressive NUT midline carcinoma

Precision medicine, which custom-tailors therapies to the needs of individual patients, is becoming more and more important in cancer therapy. Today, molecular-biological diagnostics can precisely identify alterations in tumor cells.

26 Sep 2017

FDA grants accelerated approval to new drug for treating relapsed follicular lymphoma

The U.S. Food and Drug Administration today granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies.

14 Sep 2017

Scientists find new strategy for overcoming resistance to drugs in lung cancer patients

Research at the University of Southern Denmark has revealed that a new combination of clinically tested drugs inhibits the growth of tumors, thereby potentially improving patients' survival.

8 Sep 2017

Studies reveal strategies for using shingles vaccine in arthritis patients

New research indicates that the live varicella-zoster vaccine--which is given to protect against shingles--elicits robust immune responses in patients when administered several weeks prior to the start of treatment with the arthritis drug tofacitinib.

28 Aug 2017

Collaborative project reaches milestone halfway point in constructing Kinase Chemogenomic Set

The Structural Genomics Consortium at the University of North Carolina at Chapel Hill (SGC-UNC), in partnership with the DiscoverX Corporation, has reached the milestone halfway point in its development of the Kinase Chemogenomic Set, a potent group of inhibitors which allow deeper exploration of the human kinome, a family of enzymes critical to understanding human disease and developing new therapies.

26 Aug 2017

Astex celebrates as breast cancer drug gets European marketing approval

Astex Pharmaceuticals, a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received marketing approval in Europe for Kisqali (ribociclib) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) locally advanced or metastatic breast cancer.